Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes

Masonic Medical Research Laboratory Utica, New York 13501, USA. ca@mmrl.edu

OBJECTIVES: This study sought to elucidate the cellular and ionic basts for erythromycin-induced long QT syndrome. BACKGROUND: Erythromycin is known to produce long QTU intervals on the electrocardiogram (ECG) and to be associated with the development of torsade de pointes (TdP). The mechanisms responsible for the adverse effects of this widely used antibiotic are not well defined. METHODS: The present study used microelectrode and whole-cell patch-clamp techniques to assess the effects of erythromycin on epicardial, endocardial and M cells in transmural strips, arterially perfused wedges and single myocytes isolated from the canine left ventricle. RESULTS: In isolated strips, erythromycin (10 to 100 micrograms/ml) produced a much more pronounced prolongation of the action potential duration (APD) in M cells than in endocardial and epicardial cells, resulting in the development of a large dispersion of repolarization across the ventricular wall at slow stimulation rates. Erythromycin (50 to 100 micrograms/ml) induced early after depolarizations (EADs) in cells in the M (20%) but not epicardial or endocardial regions in transmural strips of ventricular free wall. Erythromycin (100 micrograms/ml) also caused APD prolongation and a transmural dispersion of repolarization, but not EADs, in intact arterially perfused wedges of canine left ventricle. These changes were attended by the development of a long QT interval on the transmural ECG. A polymorphic ventricular tachycardia closely resembling TdP was readily and reproducibly induced after erythromycin but not before. Whole-cell patch-clamp techniques, used to examine the effects of erythromycin on myocytes isolated from the M region, showed a potent effect of the drug to inhibit the rapidly activating component (IK(r)) but not the slowly activating component (IKs) of the delayed rectifier potassium current (IK). The inward rectifier current (IK1) was unaffected. CONCLUSIONS: Our data demonstrate a preferential response of M cells to the class III actions of erythromycin, due principally to the effect of the drug to inhibit IK(r) in a population of cells largely devoid of IKs. Our findings indicate that erythromycin thus produces long QT intervals as well as a prominent dispersion of repolarization across the ventricular wall, setting the stage for induction of TdP-like tachyarrhythmias displaying characteristics typical of reentry.

This article has been cited by other articles:

				A. Burashnikov, W. Shimizu, and C. Antzelevitch Fever Accentuates Transmural Dispersion of Repolarization and Facilitates Development of Early Afterdepolarizations and Torsade de Pointes Under Long-QT Conditions Circ Arrhythmia Electrophysiol, August 1, 2008; 1(3): 202 - 208. [Abstract] [Full Text] [PDF]

				B. D. Guth Preclinical Cardiovascular Risk Assessment in Modern Drug Development Toxicol. Sci., May 1, 2007; 97(1): 4 - 20. [Full Text] [PDF]

				M. B. Thomsen, A. Oros, M. Schoenmakers, J. M. van Opstal, J. N. Maas, J. D.M. Beekman, and M. A. Vos Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation Cardiovasc Res, February 1, 2007; 73(3): 521 - 530. [Abstract] [Full Text] [PDF]

				M. Viitasalo, L. Oikarinen, H. Swan, H. Vaananen, J. Jarvenpaa, H. Hietanen, J. Karjalainen, and L. Toivonen Effects of Beta-Blocker Therapy on Ventricular Repolarization Documented by 24-h Electrocardiography in Patients With Type 1 Long-QT Syndrome J. Am. Coll. Cardiol., August 15, 2006; 48(4): 747 - 753. [Abstract] [Full Text] [PDF]

				T. Wisialowski, K. Crimin, J. Engtrakul, J. O'Donnell, B. Fermini, and A. A. Fossa Differentiation of Arrhythmia Risk of the Antibacterials Moxifloxacin, Erythromycin, and Telithromycin Based on Analysis of Monophasic Action Potential Duration Alternans and Cardiac Instability J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 352 - 359. [Abstract] [Full Text] [PDF]

				T. Aiba, W. Shimizu, M. Inagaki, T. Noda, S. Miyoshi, W.-G. Ding, D. P. Zankov, F. Toyoda, H. Matsuura, M. Horie, et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil J. Am. Coll. Cardiol., January 18, 2005; 45(2): 300 - 307. [Abstract] [Full Text] [PDF]

				C. Van Mieghem, M. Sabbe, and D. Knockaert The Clinical Value of the ECG in Noncardiac Conditions Chest, April 1, 2004; 125(4): 1561 - 1576. [Abstract] [Full Text] [PDF]

				Y. Fukuda, S. Miyoshi, K. Tanimoto, K. Oota, K. Fujikura, M. Iwata, A. Baba, Y. Hagiwara, T. Yoshikawa, H. Mitamura, et al. Autoimmunity against the second extracellular loop of beta1-adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1090 - 1100. [Abstract] [Full Text] [PDF]

				C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, R. J. Goodrow Jr, et al. Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S65 - S83. [Abstract] [PDF]

				D. J. Milan, T. A. Peterson, J. N. Ruskin, R. T. Peterson, and C. A. MacRae Drugs That Induce Repolarization Abnormalities Cause Bradycardia in Zebrafish Circulation, March 18, 2003; 107(10): 1355 - 1358. [Abstract] [Full Text] [PDF]

				A. N. Katchman, K. A. McGroary, M. J. Kilborn, C. A. Kornick, P. L. Manfredi, R. L. Woosley, and S. N. Ebert Influence of Opioid Agonists on Cardiac Human Ether-a-go-go-related Gene K+ Currents J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 688 - 694. [Abstract] [Full Text] [PDF]

				P. Milberg, L. Eckardt, H.-J. Bruns, J. Biertz, S. Ramtin, N. Reinsch, D. Fleischer, P. Kirchhof, L. Fabritz, G. Breithardt, et al. Divergent Proarrhythmic Potential of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 Repolarization Prevents Early Afterdepolarizations and Torsade de Pointes J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 218 - 225. [Abstract] [Full Text] [PDF]

				C. Antzelevitch Sympathetic modulation of the long QT syndrome Eur. Heart J., August 2, 2002; 23(16): 1246 - 1252. [PDF]

				W. A. Volberg, B. J. Koci, W. Su, J. Lin, and J. Zhou Blockade of Human Cardiac Potassium Channel Human Ether-a-go-go-Related Gene (HERG) by Macrolide Antibiotics J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 320 - 327. [Abstract] [Full Text] [PDF]

				C. Antzelevitch Heterogeneity of cellular repolarization in LQTS: the role of M cells Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K2 - K16. [Abstract] [PDF]

				M.-D. Drici Influence of gender on drug-acquired long QT syndrome Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K41 - K47. [Abstract] [PDF]

				M.R. Rosen Isolated tissue models and proarrhythmia Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K64 - K69. [Abstract] [PDF]

				B. Darpo Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K70 - K80. [Abstract] [PDF]

				S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology Eur. Heart J., August 2, 2001; 22(16): 1374 - 1450. [PDF]

				L. M Hondeghem, K. Dujardin, and F. De Clerck Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia Cardiovasc Res, May 1, 2001; 50(2): 345 - 353. [Abstract] [Full Text] [PDF]

				S. C. Verduyn, J. M. v. Opstal, J. D. Leunissen, and M. A. Vos Assessment of the Pro-Arrhythmic Potential of Anti-Arrhythmic Drugs: An Experimental Approach Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 89 - 97. [PDF]

				K. Yamamoto, T. Tamura, R. Imai, and M. Yamamoto Acute Canine Model for Drug-Induced Torsades de Pointes in Drug Safety Evaluation--Influences of Anesthesia and Validation with Quinidine and Astemizole Toxicol. Sci., March 1, 2001; 60(1): 165 - 176. [Abstract] [Full Text] [PDF]

				H. Ohtani, C. Taninaka, E. Hanada, H. Kotaki, H. Sato, Y. Sawada, and T. Iga Comparative Pharmacodynamic Analysis of Q-T Interval Prolongation Induced by the Macrolides Clarithromycin, Roxithromycin, and Azithromycin in Rats Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2630 - 2637. [Abstract] [Full Text]

				A Woywodt, U Grommas, W Buth, and W Rafflenbeul QT prolongation due to roxithromycin Postgrad. Med. J., October 1, 2000; 76(900): 651 - 653. [Full Text]

				W. Shimizu and C. Antzelevitch Effects of a K+ Channel Opener to Reduce Transmural Dispersion of Repolarization and Prevent Torsade de Pointes in LQT1, LQT2, and LQT3 Models of the Long-QT Syndrome Circulation, August 8, 2000; 102(6): 706 - 712. [Abstract] [Full Text] [PDF]

				P. G.A. Volders, M. A. Vos, B. Szabo, K. R. Sipido, S.H.M. de Groot, A. P.M. Gorgels, H. J.J. Wellens, and R. Lazzara Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts Cardiovasc Res, June 1, 2000; 46(3): 376 - 392. [Full Text] [PDF]

				W. Shimizu and C. Antzelevitch Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome J. Am. Coll. Cardiol., March 1, 2000; 35(3): 778 - 786. [Abstract] [Full Text] [PDF]

				J. Merot, F. Charpentier, J.-M. Poirier, G. Coutris, and J. Weissenburger Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol Cardiovasc Res, November 1, 1999; 44(2): 303 - 314. [Abstract] [Full Text] [PDF]

				A. Burashnikov and C. Antzelevitch Differences in the electrophysiologic response of four canine ventricular cell types to {alpha}1-adrenergic agonists Cardiovasc Res, September 1, 1999; 43(4): 901 - 908. [Abstract] [Full Text] [PDF]

				E. A. Sosunov, R. Z. Gainullin, P. Danilo Jr., E. P. Anyukhovsky, M. Kirchengast, and M. R. Rosen Electrophysiological Effects of LU111995 on Canine Hearts: In Vivo and In Vitro Studies J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 146 - 152. [Abstract] [Full Text]

				A. Mishra, H. S. Friedman, and A. K. Sinha The Effects of Erythromycin on the Electrocardiogram Chest, April 1, 1999; 115(4): 983 - 986. [Abstract] [Full Text] [PDF]

				W. Shimizu and C. Antzelevitch Cellular and Ionic Basis for T-Wave Alternans Under Long-QT Conditions Circulation, March 23, 1999; 99(11): 1499 - 1507. [Abstract] [Full Text] [PDF]

				M. Khalifa, B. Drolet, P. Daleau, C. Lefez, M. Gilbert, S. Plante, G. E. O'Hara, O. Gleeton, B. A. Hamelin, and J. Turgeon Block of Potassium Currents in Guinea Pig Ventricular Myocytes and Lengthening of Cardiac Repolarization in Man by the Histamine H1 Receptor Antagonist Diphenhydramine J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 858 - 865. [Abstract] [Full Text]

				P. Geelen, B. Drolet, E. Lessard, P. Gilbert, G. E. O'Hara, and J. Turgeon Concomitant Block of the Rapid (IKr) and Slow (IKs) Components of the Delayed Rectifier Potassium Current is Associated With Additional Drug Effects on Lengthening of Cardiac Repolarization Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(3): 143 - 150. [Abstract] [PDF]

				M.-D. Drici, B. C. Knollmann, W.-X. Wang, and R. L. Woosley Cardiac Actions of Erythromycin: Influence of Female Sex JAMA, November 25, 1998; 280(20): 1774 - 1776. [Abstract] [Full Text] [PDF]

				W. Shimizu and C. Antzelevitch Cellular Basis for the ECG Features of the LQT1 Form of the Long-QT Syndrome : Effects of ß-Adrenergic Agonists and Antagonists and Sodium Channel Blockers on Transmural Dispersion of Repolarization and Torsade de Pointes Circulation, November 24, 1998; 98(21): 2314 - 2322. [Abstract] [Full Text] [PDF]

				G.-X. Yan, W. Shimizu, and C. Antzelevitch Characteristics and Distribution of M Cells in Arterially Perfused Canine Left Ventricular Wedge Preparations Circulation, November 3, 1998; 98(18): 1921 - 1927. [Abstract] [Full Text] [PDF]

				G.-X. Yan and C. Antzelevitch Cellular Basis for the Normal T Wave and the Electrocardiographic Manifestations of the Long-QT Syndrome Circulation, November 3, 1998; 98(18): 1928 - 1936. [Abstract] [Full Text] [PDF]

				L. Eckardt, W. Haverkamp, M. Borggrefe, and G. Breithardt Experimental models of torsade de pointes Cardiovasc Res, July 1, 1998; 39(1): 178 - 193. [Abstract] [Full Text] [PDF]

				Z. Desta, T. Kerbusch, N. Soukhova, E. Richard, J.-W. Ko, and D. A Flockhart Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 428 - 437. [Abstract] [Full Text]

				W. Shimizu, T. Kurita, K. Matsuo, K. Suyama, N. Aihara, S. Kamakura, J. A. Towbin, and K. Shimomura Improvement of Repolarization Abnormalities by a K+ Channel Opener in the LQT1 Form of Congenital Long-QT Syndrome Circulation, April 28, 1998; 97(16): 1581 - 1588. [Abstract] [Full Text] [PDF]

				N. El-Sherif, M. Chinushi, E. B. Caref, and M. Restivo Electrophysiological Mechanism of the Characteristic Electrocardiographic Morphology of Torsade de Pointes Tachyarrhythmias in the Long-QT Syndrome : Detailed Analysis of Ventricular Tridimensional Activation Patterns Circulation, December 16, 1997; 96(12): 4392 - 4399. [Abstract] [Full Text]

				W. Shimizu and C. Antzelevitch Sodium Channel Block With Mexiletine Is Effective in Reducing Dispersion of Repolarization and Preventing Torsade de Pointes in LQT2 and LQT3 Models of the Long-QT Syndrome Circulation, September 16, 1997; 96(6): 2038 - 2047. [Abstract] [Full Text]

				S. Sicouri, S. Moro, and M. V. Elizari d-Sotalol Induces Marked Action Potential Prolongation and Early Afterdepolarizations in M but Not Epicardial or Endocardial Cells of the Canine Ventricle Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(1): 27 - 37. [Abstract] [PDF]

				C. Antzelevitch The M Cell Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(1): 73 - 76. [PDF]